Quantcast

Latest Veridex LLC Stories

2009-07-13 07:45:00

RARITAN, N.J., July 13 /PRNewswire/ -- Measuring the change in circulating tumor cell (CTC) count can accurately predict the prognosis and survival in patients with metastatic breast cancer (MBC), according to a newly published report in the July 10 issue of the Journal of Clinical Oncology. The retrospective study compared how well CTCs and a more sensitive than conventional modality, fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), predicted survival in...

2009-05-07 08:00:00

Proprietary Veridex Technology is the First Cancer Diagnostic Test to Automate and Capture Circulating Tumor Cells RARITAN, N.J., May 7 /PRNewswire/ -- Veridex, LLC announced today that the CellSearch(R) System to measure circulating tumor cells (CTCs) will be offered at Florida Cancer Specialists (FCS), the largest privately-owned oncology and hematology practice in Florida. Veridex's CellSearch(R) test is used to predict survival in patients with metastatic breast, colorectal or prostate...

2008-11-12 12:00:07

RARITAN, N.J., Nov. 12 /PRNewswire/ -- Veridex, LLC announced today that the technology used in the CellSearch(R) System to measure circulating tumor cells (CTCs) was ranked as the top medical innovation for 2009 by the Cleveland Clinic, a leading multispecialty academic medical center. The ranking is based on technologies likely to have a significant impact on health care next year. The prestigious annual recognition follows a rigorous selection process by a panel of Cleveland Clinic...

2008-08-01 18:00:36

Immunicon Corporation (OTCBB:IMMC.OB) announced today that Immunicon Corporation and its wholly-owned subsidiaries completed their previously announced sale of substantially all of their assets to Veridex, LLC ("Veridex") in a sale conducted under the provisions of Section 363 of the U.S. Bankruptcy Code and approved by the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") on July 30, 2008. Veridex paid Immunicon $31,320,023 in cash, subject to certain...

2008-08-01 18:00:36

RARITAN, N.J., Aug. 1 /PRNewswire/ -- Veridex, LLC announced today it has completed its previously announced acquisition of substantially all of the assets of Immunicon Corporation (BULLETIN BOARD: IMMC) and its wholly-owned subsidiaries. The assets acquired include intellectual property, product inventory and clinical data as well as all technologies related to the CellSearch(TM) System, the first diagnostic test to automate the detection and enumeration of circulating tumor cells...

2008-07-24 18:00:23

RARITAN, N.J., July 25 /PRNewswire/ -- An international, prospective clinical trial found the number of circulating tumor cells (CTCs) is a strong indicator of progression-free and overall survival among metastatic colorectal cancer patients, according to a report published in the July 1 issue of the Journal of Clinical Oncology. The study, conducted in the US, the Netherlands, and the United Kingdom, found that metastatic colorectal cancer patients with fewer than three circulating tumor...

2008-07-18 00:00:15

Research and Markets Laura Wood, Senior Manager Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 press@researchandmarkets.com Logo: http://www.researchandmarkets.com Research and Markets (http://www.researchandmarkets.com/research/ 8d3dd7/commercializing_mo) has announced the addition of the "Commercializing Molecular Diagnostics: Products, Services, Companies and Global Market" report to their offering. This report is about the molecular diagnostics...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.